Adverse ocular events related to belantamab mafodotin for treatment of multiple myeloma

被引：0
|
作者：
Lent-Schochet, Daniella [1 ]
Mokhashi, Nikita [1 ]
Vidyasagar, Nitin [1 ]
Farooq, Asim [1 ]
机构：
[1] Univ Chicago Med, Chicago, IL USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4100
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
    Wahab, Ahsan
    Rafae, Abdul
    Mushtaq, Kamran
    Masood, Adeel
    Ehsan, Hamid
    Khakwani, Maria
    Khan, Aqsa
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
    McCurdy, Arleigh
    Visram, Alissa
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (06) : 306 - 318
  • [23] The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
    Arleigh McCurdy
    Alissa Visram
    Current Hematologic Malignancy Reports, 2022, 17 : 306 - 318
  • [24] Ocular surface changes associated with belantamab mafodotin treatment
    Ghalibafan, Seyyedehfatemeh
    Osei, Kwaku A.
    Hoffman, James E.
    Sabater, Alfonso L.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 261 (11) : 3201 - 3204
  • [25] Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma
    Abeykoon, Jithma P.
    Vaxman, Julia
    Patel, Sanjay V.
    Kumar, Shaji
    Malave, Gabriella C.
    Young, Kimberly S.
    Ailawadhi, Sikander
    Larsen, Jeremy T.
    Dispenzieri, Angela
    Muchtar, Eli
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Leung, Nelson
    Warsame, Rahma
    Go, Ronald S.
    Bergsagel, Leif
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kapoor, Prashant
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (01) : 95 - 99
  • [26] Ocular surface changes associated with belantamab mafodotin treatment
    Seyyedehfatemeh Ghalibafan
    Kwaku A. Osei
    James E. Hoffman
    Alfonso L. Sabater
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261 : 3201 - 3204
  • [27] Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Kanellias, Nikolaos
    Eleutherakis-Papaiakovou, Evangelos
    Roussou, Maria
    Psarros, Giorgos
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (03) : 502 - 504
  • [28] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
    Condorelli, Annalisa
    Garibaldi, Bruno
    Gagliano, Caterina
    Romano, Alessandra
    Del Fabro, Vittorio
    Parrinello, Nunziatina Laura
    Longo, Antonio
    Cosentino, Sebastiano
    Di Raimondo, Francesco
    Conticello, Concetta
    ACTA HAEMATOLOGICA, 2024, 147 (04) : 493 - 498
  • [29] Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients
    Bausell, Rebecca B.
    Soleimani, Arshia
    Vinnett, Alfred
    Baroni, Mariana D.
    Staub, Sheila A.
    Binion, Katrina
    Jeng, Bennie H.
    Badros, Ashraf Z.
    Munir, Wuqaas M.
    EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE, 2021, 47 (06): : 362 - 365
  • [30] The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
    Becnel, Melody R.
    Lee, Hans C.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
12345